Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - pemetrexed disodium, quantity: 551.45 mg (equivalent: pemetrexed, qty 500 mg) - injection, powder for - excipient ingredients: hydrochloric acid; mannitol; sodium hydroxide - malignant pleural mesothelioma,pemetrexed, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,non-small cell lung cancer,pemetrexed in combination with cisplatin is indicated for initial treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,pemetrexed as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pemetrexed disodium hemipentahydrate, quantity: 604 mg (equivalent: pemetrexed, qty 500 mg) - injection, powder for - excipient ingredients: mannitol; hydrochloric acid; sodium hydroxide - malignant pleural mesothelioma,pemetrexed, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,non-small cell lung cancer (nsclc),pemetrexed, in combination with cisplatin, is indicated for initial treatment of patients with locally advanced or metastatic nsclc other than predominantly squamous cell histology.,pemetrexed, as monotherapy, is indicated for the treatment of patients with locally advanced or metastatic nsclc other than predominantly squamous cell histology after prior platinum-based chemotherapy.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - pemetrexed disodium hemipentahydrate -

Stati Uniti - Ingliż - NLM (National Library of Medicine)

salix pharmaceuticals, inc - balsalazide disodium (unii: 1xl6bji034) (balsalazide - unii:p80al8j7zp) - balsalazide disodium 1.1 g - giazo is indicated for the treatment of mildly to moderately active ulcerative colitis in male patients 18 years of age and older. limitations of use: giazo is contraindicated in patients with hypersensitivity to salicylates, aminosalicylates or their metabolites, or to any of the components of giazo tablets [see description (11)]. risk summary published data from meta-analyses, cohort studies and case series on the use of mesalamine, the active moiety of giazo, during pregnancy have not reliably informed an association with mesalamine and major birth defects, miscarriage, or adverse maternal or fetal outcomes (see data) . there are adverse effects on maternal and fetal outcomes associated with ulcerative colitis in pregnancy (see clinical considerations) . in animal reproduction studies, there were no adverse developmental effects observed after oral administration of balsalazide disodium in pregnant rats and rabbits during organogenesis at doses up to 2.4 and 4.7 times, respectively, the maximum recommended

Stati Uniti - Ingliż - NLM (National Library of Medicine)

3lab, inc. - titanium dioxide (unii: 15fix9v2jp) (titanium dioxide - unii:15fix9v2jp) - titanium dioxide 78.6 mg in 1 ml - helps prevent sunburn. if used as directed with other sun protection measures (see directions), decreases the risk of skin cancer and early skin aging caused by the sun.

Stati Uniti - Ingliż - NLM (National Library of Medicine)

intermune, inc. - amphotericin b (unii: 7xu7a7droe) (amphotericin b - unii:7xu7a7droe) - injection, lipid complex - 50 mg in 10 ml - amphotec is indicated for the treatment of invasive aspergillosis in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin b deoxycholate in effective doses, and in patients with invasive aspergillosis where prior amphotericin b deoxycholate therapy has failed. amphotec should not be administered to patients who have documented hypersensitivity to any of its components, unless, in the opinion of the physician, the advantages of using amphotec outweigh the risks of hypersensitivity.

Stati Uniti - Ingliż - NLM (National Library of Medicine)

carilion materials management - etidronate disodium (unii: m16pxg993g) (etidronic acid - unii:m2f465roxu) - etidronate disodium 200 mg - etidronate disodium tablets, usp are indicated for the treatment of symptomatic paget’s disease of bone and in the prevention and treatment of heterotopic ossification following total hip replacement or due to spinal cord injury. etidronate disodium tablets are not approved for the treatment of osteoporosis. etidronate disodium tablets are indicated for the treatment of symptomatic paget’s disease of bone. etidronate disodium therapy usually arrests or significantly impedes the disease process as evidenced by: in addition, reductions in pagetically elevated cardiac output and skin temperature have been observed in some patients. in many patients, the disease process will be suppressed for a period of at least one year following cessation of therapy. the upper limit of this period has not been determined. the effects of the etidronate disodium treatment in patients with asymptomatic paget’s disease have not been studied. however, etidronate disodium treatment of such patients may be warranted if extensive invo

Stati Uniti - Ingliż - NLM (National Library of Medicine)

dechra veterinary products - clodronate disodium (unii: n030400h8j) (clodronic acid - unii:0813bz6866) - clodronate disodium 60 mg in 1 ml - indication: for the control of clinical signs associated with navicular syndrome in horses. contraindications: horses with hypersensitivity to clodronate disodium should not receive osphos. do not use in horses with impaired renal function or with a history of renal disease.

Stati Uniti - Ingliż - NLM (National Library of Medicine)

asclemed usa, inc. - epinephrine (unii: ykh834o4bh) (epinephrine - unii:ykh834o4bh) - epinephrine 1 mg in 1 ml - adrenalin ® is available as a single-use 1 ml vial. the 1 ml vial is for intramuscular, subcutaneous, and intraocular use. emergency treatment of allergic reactions (type i), including anaphylaxis, which may result from allergic reactions to insect stings, biting insects, foods, drugs, sera, diagnostic testing substances and other allergens, as well as idiopathic anaphylaxis or exercise-induced anaphylaxis. the signs and symptoms associated with anaphylaxis include flushing, apprehension, syncope, tachycardia, thready or unobtainable pulse associated with hypotension, convulsions, vomiting, diarrhea and abdominal cramps, involuntary voiding, airway swelling, laryngospasm, bronchospasm, pruritus, urticaria or angioedema, swelling of the eyelids, lips, and tongue. induction and maintenance of mydriasis during intraocular surgery. none. teratogenic effects: pregnancy category c. there are no adequate and well-controlled studies in pregnant women. epinephrine should be used during pregnancy only if

Stati Uniti - Ingliż - NLM (National Library of Medicine)

par pharmaceutical, inc. - epinephrine (unii: ykh834o4bh) (epinephrine - unii:ykh834o4bh) - epinephrine 1 mg in 1 ml - emergency treatment of allergic reactions (type i), including anaphylaxis, which may result from insect stings or bites, foods, drugs, sera, diagnostic testing substances and other allergens, as well as idiopathic anaphylaxis or exercise-induced anaphylaxis.  adrenalinis indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. none. risk summary prolonged experience with epinephrine use in pregnant women over several decades, based on published literature, do not identify a drug associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.  however, there are risks to the mother and fetus associated with epinephrine use during labor or delivery (see clinical considerations) .  in animal reproduction studies, epinephrine administered by the subcutaneous route to pregnant rabbits, mice, and hamsters, during the period of organogenesis, resulted in adverse developmental effects (including gastroschisis, and embryonic lethalit